Biomarkers for Clinical Trial Readiness in Acid Sphingomyelinase Deficiency Current Evidence and Roadmaps For Future Development
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Krista Casazza und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Acid sphingomyelinase deficiency (ASMD) is a multisystem lysosomal disorder caused by biallelic SMPD1 variants resulting in deficient lysosomal acid sphingomyelinase activity. Historically, biomarker needs for this disorder were focused on patient diagnosis and disease description, but the recent approval of olipudase alfa enzyme replacement therapy (ERT) has shifted these needs toward pharmacodynamic assessment, patient stratification, organ-specific monitoring, and evaluation of emerging therapies. This review critically assesses the current ASMD biomarker landscape and defines priorities for clinical-trial readiness using the FDA-NIH BEST framework as a conceptual guide. Acid sphingomyelinase activity and SMPD1 genetic analysis remain foundational diagnostic measures, whereas LysoSM, LysoSM-509, CHITO, CCL18, platelet count, lipid profiles (LDL-C, HDL-C), organ volumes, liver function (ALT/AST) and pulmonary measures provide complementary information on visceral disease burden and treatment response. Olipudase alfa ERT has demonstrated responsiveness across biochemical, imaging, hematologic, metabolic, and pulmonary domains, but the capacity of these measures to predict long-term outcomes or support use as surrogate endpoints remains incompletely defined. In addition, this ERT does not impact the central nervous system (CNS), and there are no validated biomarkers that reliably measures CNS disease activity, progression, or therapeutic response. Priority candidates include neurofilament light chain, glial and myelin-associated proteins, measures of neuroinflammation, analysis of selected sphingomyelin species, quantitative neuroimaging, and extracellular-vesicle approaches. Future progress in biomarker development will require harmonized longitudinal studies that pair biomarkers with neurological, functional, digital, and patient-reported clinical outcome assessments. Important priorities include identification and validation of CNS-specific biomarkers, assay standardization for all biomarkers, prospective natural-history integration, mechanism-specific pharmacodynamic linkage, and development of regulatory strategies aligned with a clearly defined context of use.
Zitieren
APA
Casazza, K., Ledesma, M. D., Hopkin, J., Baker, J., Laffoon, S., Mathieson, T., Cowie, S., Guadioso, A., & Schuchman, E. H. (2026). Biomarkers for Clinical Trial Readiness in Acid Sphingomyelinase Deficiency Current Evidence and Roadmaps For Future Development. Medical Research Archives. https://doi.org/10.18103/mra.2026.0795
Vancouver
Casazza K, Ledesma MD, Hopkin J, Baker J, Laffoon S, Mathieson T, et al. Biomarkers for Clinical Trial Readiness in Acid Sphingomyelinase Deficiency Current Evidence and Roadmaps For Future Development. Medical Research Archives. 2026. doi:10.18103/mra.2026.0795
BibTeX
@article{Casazza2026,
author = {Casazza, Krista and Ledesma, Maria Dolores and Hopkin, Justin and Baker, Joshua and Laffoon, Steven and Mathieson, Toni and Cowie, Sandra and Guadioso, Angel and Schuchman, Edward H},
title = {Biomarkers for Clinical Trial Readiness in Acid Sphingomyelinase Deficiency Current Evidence and Roadmaps For Future Development},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0795}
}
EUVIMED